Merrimack Pharmaceuticals' investigational treatment MM-111 won two orphan-drug designations from the FDA. The drug is in midstage development for the treatment for esophageal cancer as well as for gastric and gastroesophageal junction cancers. The designation would give MM-111 seven years of market exclusivity and other benefits upon approval by the FDA.

Related Summaries